Clinical Commissioning Policy: Teriparatide for osteoporosis

Document first published:: 21 January 2021
Page updated:: 23 August 2024
Topic:: Specialised commissioning
Publication type:: Policy or strategy

Teriparatide is recommended to be available as a routine commissioning treatment option for osteoporosis in men (adults).

Document

Clinical Commissioning Policy: Teriparatide for osteoporosis

Clinical Commissioning Policy: Teriparatide for osteoporosis

PDF
168 KB
9 pages

Summary

This policy replaces the previous interim clinical commissioning policy statement.

Updated 23 August 2024.